Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs
07 avr. 2024 14h00 HE
|
BioNTech SE
Drei-Jahres-Follow-up-Daten aus einer nichtkommerziellen Phase-1-Studie mit dem individualisierten mRNA-basierten Krebsimpfstoff-Kandidaten Autogene Cevumeran (BNT122, RO7198457) bei Patientinnen und...
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
07 avr. 2024 14h00 HE
|
BioNTech SE
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...
METC extended through March 31, 2025
02 avr. 2024 09h36 HE
|
Prospectors & Developers Association of Canada (PDAC)
The Government of Canada announced an extension to the Mineral Exploration tax Credit (METC) through March 31, 2025.
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11 mars 2024 08h00 HE
|
Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
SLAM CEO Talking About Mine Road Acquisition at PDAC
04 mars 2024 14h51 HE
|
SLAM Exploration Ltd.
MIRAMICHI, New Brunswick, March 04, 2024 (GLOBE NEWSWIRE) -- SLAM Exploration Ltd. (TSXV-SXL) (“SLAM” or the “Company”) announces that CEO Mike Taylor is doing a presentation at The Atlantic Edge...
American Rare Earths to present at two leading industry conferences in March PDAC and International Battery Seminar
27 févr. 2024 09h03 HE
|
American Rare Earths
DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | ADRs - OTCQX: AMRRY | Common Shares - OTCQB: ARRNF) (“ARR” or the “Company”) executives will participate in two upcoming...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
07 déc. 2023 19h51 HE
|
EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
26 nov. 2023 23h37 HE
|
EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
PDAC announces 2024 Award Recipients
09 nov. 2023 10h00 HE
|
Prospectors & Developers Association of Canada (PDAC)
2024 PDAC Award Recipients: Osisko Mining - Wabun Tribal Council - O3 Mining - Lundin Group - Victoria Gold Corp.
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...